A case of inflammatory breast cancer following augmentation mammoplasty with silicone gel implants

Abstract

A 54-year-old-woman who underwent augmentation mammoplasty with silicone gel implants 30 years previously, visited our hospital with complaints of bloody nipple discharge, redness and itching of her right breast. Cancer of the right breast was diagnosed by dynamic magnetic resonance imaging (MRI) examination with Gadolinium (Gd)-DTPA enhancement. Radical mastectomy was subsequently performed. The histopathological findings demonstrated scirrhous and inflammatory breast cancer with invasion of dermal lymphatics.

In Vivo and In Vitro Measurement of Apoptosis in Breast Cancer Cells Using99mTc-EC-Annexin V

“…[1][2][3][4][5][6] However, tumor markers are influenced by other factors, so that they lack sensitivity and specificity, while tissue biopsy is an invasive process associated with sampling errors. Conventional x-ray mammography has been shown to reduce mortality of breast cancer by about 30% in women older than 50 years of age and by 17% in women ages 40-50.…”

Invasive micropapillary carcinomas arising 42 years after augmentation mammoplasty: A case report and literature review

“…With respect to imaging modalities, mammography may not be a good screening tool in augmented women, because cancer in augmented women is significantly less likely to present as a mammographic abnormality in the absence of physical findings [ 3 , 10 , 24 ]. Mammography was impossible for our patient, due to small and contractural breasts.…”

“…Ultrasonography with Color Doppler can be useful for distinguishing cancer from the siliconoma. In addition, MRI using dynamic Gd-DTPA enhancement was found to be useful for the diagnosis of breast cancer because of its high quality and resolution and made it possible to determine whether a lesion is malignant or not [ 3 ], although it was not possible to diagnose all four lesions as cancer.…”

Breast cancer risk in women treated with augmentation mammoplasty (Review)

“…Some authors report in singular cases that cancers in augmented women usually are more advanced at the time of detection (13,14), whereas others have reported no significant difference in tumor size or stage at the time of diagnosis in augmented women compared to non-augmented women.…”

“…Incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe, and are high (greater than 80 per 100,000) in developed regions of the world (except Japan) and low (less than 40 per 100,000) in most of the developing regions. The range of mortality rates is much less (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) per 100,000) because of the more favorable survival of breast cancer in (high-incidence) developed regions. As a result, breast cancer ranks as the fifth cause of death from cancer overall (458,000 deaths), but it is still the most frequent cause of cancer death in women in both developing (269,000 deaths, 12.7% of total) and developed regions, where the estimated 189,000 deaths is almost equal to the estimated number of deaths from lung cancer (188,000 deaths) (1).…”